ReviewFrontiers in pharmacology2020
Mechanisms and Efficacy of Chinese Herbal Medicines in Chronic Kidney Disease.
Review in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Paeonia genus: a systematic review of active ingredients, pharmacological effects and mechanisms, and clinical applications for the treatment of cancer.Archives of pharmacal research · 2024Pooled it
- Bone transcriptomics reveals that juzentaihoto remodels and activates multiple pathways in Klotho-deficient mice.Bone reports · 2026Article
- A Data Mining Approach on Polypharmacy and Drug-drug Interactions of Common Diabetes Medications.Current drug metabolism · 2025Review
- Metabolic reprogramming and renal fibrosis: what role might Chinese medicine play?Chinese medicine · 2024Review
- Shenshuaikang enema restores the intestinal barrier and microbiota-gut-kidney axis balance to alleviate chronic kidney disease via NF-κB pathway.Frontiers in pharmacology · 2024Article
- Network pharmacology and multi-omics validation of the Jianpi-Yishen formula in the treatment of chronic kidney disease.Frontiers in immunology · 2024Article
- Therapeutic effects of Kangxian Yanshen formula on patients with chronic kidney disease stages 3-4: a retrospective cohort study.Frontiers in medicine · 2024Article
- An integrated strategy of spectrum-effect relationship and near-infrared spectroscopy rapid evaluation based on back propagation neural network for quality control of Paeoniae Radix Alba.Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2023Article
- Pharmacological functions of salidroside in renal diseases: facts and perspectives.Frontiers in pharmacology · 2023Review
- Review
- Potential Therapeutic Strategies for Renal Fibrosis: Cordyceps and Related Products.Frontiers in pharmacology · 2022Review
- Natural products from plants and microorganisms: Novel therapeutics for chronic kidney diseaseFrontiers in pharmacology · 2022Review
- Inflammatory markers in chronic kidney disease and end stage renal disease patients.Molecular biology reports · 2021Article
- New Insights Into the Effects of Individual Chinese Herbal Medicines on Chronic Kidney Disease.Frontiers in pharmacology · 2021Review
- Chinese Herbal Medicine in the Treatment of Chronic Kidney Disease: A Narrative Review of Mechanisms and Therapeutic Potential.Iranian journal of pharmaceutical research : IJPRReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As the current treatment of chronic kidney disease (CKD) is limited, it is necessary to seek more effective and safer treatment methods, such as Chinese herbal medicines (CHMs). In order to clarify the modern theoretical basis and molecular mechanisms of CHMs, we reviewed the knowledge based on publications in peer-reviewed English-language journals, focusing on the anti-inflammatory, antioxidative, anti-apoptotic, autophagy-mediated and antifibrotic effects of CHMs commonly used in kidney disease. We also discussed recently published clinical trials and meta-analyses in this field. Based on recent studies regarding the mechanisms of kidney disease
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.